共 102 条
[1]
Torres VE(2007)Autosomal dominant polycystic kidney disease Lancet 369 1287-1301
[2]
Harris PC(2008)Clinical practice. Autosomal dominant polycystic kidney disease N Engl J Med 359 1477-1485
[3]
Pirson Y(2015)The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial Clin Exp Nephrol 19 867-877
[4]
Grantham JJ(2002)Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients Am J Kidney Dis 39 571-579
[5]
Muto S(2015)Survival after arterial embolization therapy in patients with polycystic kidney and liver disease J Nephrol 28 369-377
[6]
Kawano H(2017)Methodological issues in clinical trials of polycystic kidney disease: a focused review J Nephrol 30 363-371
[7]
Higashihara E(2012)Tolvaptan in patients with autosomal dominant polycystic kidney disease N Engl J Med 367 2407-2418
[8]
Narita I(2006)Volume progression in polycystic kidney disease N Engl J Med 354 2122-2130
[9]
Ubara Y(2017)Tolvaptan in later-stage autosomal dominant polycystic kidney disease N Engl J Med 377 1930-1942
[10]
Matsuzaki T(1997)Role of vasopressin in essential hypertension: racial differences J Hypertens 15 545-550